pharmaphorum

DECEMBER 15, 2021

The aim of the project is to develop tools that will “improve patient care, accelerate drug development, and further the understanding of the underlying pathologies of neurological diseases,” said the two partners. The post Biogen puts $15m into digital health alliance with TheraPanacea appeared first on.

Patient Care 69

Patient Care 69

The Checkup by Singlecare

APRIL 12, 2024

The short supply of this Type 2 diabetes drug has been the subject of many headlines and social media posts. clinical pharmacy program director at Harbor Health. a clinical pharmacist practitioner in Minnesota. a clinical pharmacist practitioner in Minnesota. Looking for an Ozempic shortage update?

Pharmacy Program Director 105

Pharmacy Program Director Labelling FDA Hospitals 105

pharmaphorum

FEBRUARY 16, 2021

“While there have been other efforts to develop anti-inflammatory drugs for AD, targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach.”. It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.”.

Immunization 119

Immunization 119

pharmaphorum

MARCH 15, 2022

However, companies often fall short when it comes to engaging patients in a meaningful way during the product development process. Daily Newsletter – Coverage and analysis of all the latest industry headlines. Life science companies invest a significant number of resources to engage physicians and patient advocates.

98

98

pharmaphorum

AUGUST 21, 2020

New insights into smell and taste loss symptoms, artificial intelligence and further encouraging data from a vaccine candidate hit the headlines this week as the COVID-19 coronavirus pandemic continues. Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses?

Vaccines 105

Vaccines 105

pharmaphorum

APRIL 12, 2021

While the headline figure looks significant the UK biotech will receive only €7 million up front, reflecting the fact that the drug has not yet begun clinical testing. The rest of the money will come in the form of milestone payments if agreed development, regulatory and commercial targets are met.

52

52

pharmaphorum

JANUARY 18, 2022

Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus. It will be developed by London-based Poolbeg as POLB 002. The combination of these actions can slash viral load and therefore improve disease symptoms.

Vaccines 59

Vaccines 59

pharmaphorum

JANUARY 25, 2021

The clinical research community has been disrupted in a number of ways due to COVID-19 and sparked a spirit of collaboration and innovation. Worldwide Clinical Trial’s Aman Khera gives five predictions of how clinical research could change in 2021. clinical trial diversity. public education. digitalisation.

Communication 124

Communication Patient Care FDA 124

pharmaphorum

OCTOBER 4, 2022

Novo Nordisk’s ONWARDS program for once-weekly insulin icodec comprises six phase 3a global clinical trials , including a trial with RWE involving more than 4,000 adults with type 1 or type 2 diabetes. The post Novo Nordisk achieve headline results with icodec insulin appeared first on. A 26-week extension phase is currently ongoing.

Labelling 59

Labelling 59

European Pharmaceutical Review

APRIL 14, 2023

Oligonucleotide therapeutics represent a relatively novel class of drug, with the potential to modulate drug targets that were previously considered intractable, and with the benefit of fast clinical development times. As the first speaker of the day, Dr Leberer had shared there are around “400 oligonucleotide molecules in development.”

Vaccines 92

Vaccines 92

pharmaphorum

MARCH 15, 2021

Big pharma might have dominated COVID headlines with its vaccine drive, but behind the scenes an army of SMEs has enabled the UK to respond swiftly to the pandemic.

Vaccines 52

Vaccines 52

pharmaphorum

FEBRUARY 25, 2021

Pfizer may have been making headlines with the COVID vaccine it developed with BioNTech, but it’s not the only infectious disease the big pharma is targeting. It was developed using a master “seed” virus that is similar to the TBE virus found in nature but does not cause symptoms.

FDA 66

FDA Vaccines Immunization 66

European Pharmaceutical Review

OCTOBER 30, 2023

Echoes of the global health challenges we faced during the COVID-19 pandemic still linger as new variants emerge and COVID continues to make headlines. 1 In response, much effort has gone into organising and strategising vaccine development and distribution to ensure expedited availability and equitable distribution for the future.

Vaccines 102

Vaccines 102

pharmaphorum

OCTOBER 14, 2020

The UK company made headlines earlier this year when partner Sumitomo Pharma started clinical trials of a drug candidate for obsessive compulsive disorder, said to be the first medicine developed using AI to enter testing in humans. Sumitomo’s OCD candidate, for example, went from discovery to clinical testing in just 12 months.

FDA 59

FDA 59

pharmaphorum

AUGUST 27, 2020

The Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), works with universities, research organisations, businesses, charities, and government to develop a supportive ecosystem. The common challenge is undertaking lengthy and capital-intensive phase II/III clinical trials.

Vaccines 122

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 122

pharmaphorum

SEPTEMBER 23, 2021

Development of the shot eventually fell behind mRNA rivals from BioNTech and Moderna, and Imperial eventually pivoted its efforts to development of possible boosters directed at emerging variants based on its self-assembling RNA (saRNA) platform. billion takeover of Translate Bio and $470 million acquisition of Tidal Therapeutics.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

FEBRUARY 26, 2021

Luckily, these are all things that pharma has already embraced during the pandemic, as we see in interviews with LEO Pharma’s new R&D lead Jörg Möller and data specialist Maria Chatzou Dunford, as well as experts from NIHR, Advanced Clinical and Bruntwood SciTech, among many others. . LEO Pharma’s new R&D lead on driving agility.

Vaccines 59

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 59

pharmaphorum

OCTOBER 23, 2020

Originally intended as a treatment for Ebola virus, remdesivir made headlines early on in the pandemic as the first drug to show significant improvements in recovery time in patients. The approval is supported by data from two randomised, open-label, multi-centre phase 3 clinical studies of Veklury conducted by Gilead.

Hospitals 59

Hospitals Labelling FDA 59

The People's Pharmacy

JUNE 15, 2023

Headlines proclaim that no amount of alcohol consumption is good for you–or that drinking won’t kill you. Why We Can’t Count on Alcohol for Longer Life: A systematic review of 107 trials triggered the latest rash of headlines on whether alcohol affects mortality ( JAMA Network Open, March 31, 2023 ). Bewildered?

Mayo Clinic 78

Mayo Clinic 78

pharmaphorum

DECEMBER 24, 2020

AMG 634 – a PDE4 inhibitor being investigated for TB and leprosy complication erythema nodosum leprosum (ENL) – is being licensed to Australia’s Medicines Development for Global Health (MDGH), with Amgen surrendering all rights to the drug. The post Amgen hands off leprosy, TB candidate to Australian non-profit appeared first on.

Compounding 52

Compounding 52

pharmaphorum

DECEMBER 10, 2020

Terms of the deal haven’t been disclosed, but some of the headline value is tied to clinical and regulatory milestones. All the Swiss company’s other development programmes are currently at the preclinical stage. The German pharma group is paying €1.18

Vaccines 59

Vaccines Immunization FDA 59

pharmaphorum

NOVEMBER 11, 2020

He also served as chair of AZ’s Global Chemistry Leaders Network, with responsibility for implementing strategic initiatives and collaborations, and championed developments in artificial intelligence (AI), machine learning, physics-based computation and automation.

52

52

pharmaphorum

JULY 7, 2022

The headline readout was from Cohort 1 of its ENDEAVOR trial – in 20 subjects aged four to seven – which showed a significant improvement compared to controls at one year on the North Star Ambulatory Assessment (NSAA) scale compared to a matched control group.

FDA 59

FDA 59

PQA

SEPTEMBER 9, 2022

PQA has been busy this year advancing the quality of medication use through measure development and stewardship, education, research and convening. The 2022 PQA Headlines and Highlights details our accomplishments together. Both models were developed in collaboration with the Community Pharmacy Enhanced Services Network (CPESN).

Community Pharmacies 52

Community Pharmacies Vaccines Controlled Substances FDA 52

pharmaphorum

MARCH 8, 2022

That hard-to-treat population is a key part of Gilead’s plans of extending use of TROP2-targeting Trodelvy beyond its currently-approved indication of triple-negative breast cancer (TNBC) and bladder cancer , and justify the $21 billion the company paid to buy Immunomedics, which originally developed the drug.

Chemotherapy 52

Chemotherapy Documentation Labelling 52

pharmaphorum

FEBRUARY 25, 2022

Pharma companies are now household names, having been thrust into the public’s consciousness after dominating the headlines through the pandemic. The UK pharma sector should emerge from COVID-19 with a great deal of goodwill in the bank, especially after rapidly developing vaccines that are helping to steer the world out of the pandemic.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines Patient Care 98

pharmaphorum

NOVEMBER 12, 2020

Of course, the Pfizer/BioNTech COVID-19 vaccine is just one of many in development and study is still ongoing and collecting additional safety and efficacy data. The organisations who research, develop and manufacture medicines, vaccines and health tech are our best hope of treating, preventing or one day even eradicating the virus.”.

Vaccines 87

Vaccines FDA 87

Pharmaceutical Technology

JULY 14, 2022

Even as regulatory agencies contemplate the authorization of Omicron-specific Covid-19 vaccines , existing versions continue to make headlines. Janssen Pharmaceutical Companies of Johnson and Johnson’s one-shot vaccine will now be indicated when other vaccines are not accessible or when it is clinically appropriate for adults. .

Vaccines 52

Vaccines Packaging FDA Pharmaceutical Companies 52

pharmaphorum

JUNE 20, 2022

It’s a whole host of distinct diseases with similar manifestations that are distinctly important in terms of clinical practise and responses to drugs with certain mechanisms of action,” Verdin states. ” Developing drugs is complex and expensive, often driving costs to be passed on to patients.

FDA 52

FDA 52

The Spirit Pharmacist

JULY 19, 2021

Therapies that have headliner articles in the New York Times stating the "results [of psychedelic therapies] are unprecedented in the field of mental health". It's willful ignorance as trial after trial replicates safety and profound clinical benefits.

FDA 52

FDA 52

pharmaphorum

FEBRUARY 17, 2021

Among the galaxy of analysis speculating about why ‘Project Haven’ didn’t work, a headline from Barron’s seemed to capture the root issue: ‘JP Morgan, Amazon, and Berkshire Hathaway’s Health-Care Venture Dies. Costs Remain a Problem.’. Cost” is not the problem. New Strategy starts with interoperability at a national level.

Insurance 126

Insurance Pharmaceutical Companies Pharmaceutical Companies 126

PharmaShots

MAY 29, 2023

The headline story then, as it has been lately, is one of sizeable gains for Mainland China and continuing incremental loss of share for the United States, which reflects a transformational rebalancing of scientific and scholarly contributions at the top level through the globalization of the research enterprise. in 2018 to a 4.7%

40

40

Pharmaceutical Technology

AUGUST 5, 2022

The development of therapeutics for transmissible spongiform encephalopathies (TSEs) continues to be challenged by the complex nature of these diseases. According to GlobalData’s Pharma Intelligence Center, there are only six drugs in active development for CJD, of which only one has been in clinical trials.

Vaccines 119

Vaccines Communication 119

European Pharmaceutical Review

DECEMBER 8, 2022

Hesham Abdullah, Senior Vice President, Global Head of Oncology Development at GSK commented: “The head-to-head data from the PERLA trial showed that dostarlimab combined with chemotherapy provided robust anti-tumour activity in patients with previously untreated NSCLC. Safety data of the non-squamous NSCLC clinical trial .

Chemotherapy 104

Chemotherapy 104

pharmaphorum

JULY 16, 2021

Sam Jansen explores the practical steps needed to ensure people are comfortable with virtual clinics and the tech involved. Behind the swathe of headlines lauding the way in which GPs and patients have embraced digital healthcare, there lies a somewhat uncomfortable truth. Be transparent. Build trust.

Communication 99

Communication Patient Care Vaccines 99

Hospital Pharmacy Europe

AUGUST 22, 2023

As a result, he quickly developed the necessary skills to communicate effectively with both patients and doctors – something he believes ‘benefitted me for the rest of my life’. While working at the Medicines Control Agency, he developed a strong interest in public health, epidemiology and pharmacovigilance.

Vaccines 96

Vaccines Community Pharmacies Hospitals Communication 96

pharmaphorum

OCTOBER 1, 2020

The 3 rd CAR-T approval recently hit the headlines for Kite Pharma in mantle cell lymphoma. Due to this clear clinical and commercial success, the oncology field has become saturated with companies with the hope to develop a cure… but are you aware of the new CAR-T movement beyond oncology? Download the full program here.

Medical Schools 52

Medical Schools Hospitals 52